PD-1/PD-L1 inhibitor plus chemotherapy is statistically associated with a 38% reduction in the risk of disease progression, a 32% reduction in the risk of death, and 1.6 times the probability of achieving an objective response compared to standard chemotherapy for first-line treatment of advanced NSCLC (Zhou et al., 2018). Here, PDCD1 is linked to non-small cell lung carcinoma.